Retrospective Analysis of Clinico-Epidemiological Profile of COVID 19 Associated Mucormycosis Patients: A Single Centre Experience in Southern Haryana
DOI:
https://doi.org/10.37506/j2emxk83Keywords:
COVID 19, Mucormycosis, Risk factorsAbstract
Background: A number of factors were supposed to be involved in very high rate of mucormycosis infection
in COVID 19 patients like the reduced immunity because of COVID infection itself along with use of steroids,
administration of supplemental oxygen, worsening glycemic control. This retrospective study has been undertaken to analyse the clinical and demographic profile of patients and various other factors that were involved in development of mucormycosis.
Material and Methods: This was retrospective observational study in which all patients admitted were either
suspected but came out to be negative or which were culture or histopathological proven mucormycosis cases.The data was analysed for demographic as well as clinical profile of the patients and various risk factors involved.
Results: Total 52 patients were included in the study. All of these were rhinoorbitocerebral mucormycosis patients.The mean age of mucor positive patients was 47.3 years with male to female ratio as 5:1. The comparison of risk factors among mucor positive and mucor negative patients showed that out of 30 mucor positive patients there were 18 (60%) patients with confirmed report of COVID 19 infection, 22 (73.3%) diabetic patients, 17 (56.7%)patients with recent history of steroid treatment and 11 (36.7%) patients with history of recent oxygen therapy.
Conclusion: In this study there was no statistically significant association between specific risk factors and mucorpositivity, emphasizing the multifactorial nature of mucormycosis. Further research is necessary to evaluate the complex relationship between COVID-19 infection and other factors in the development of mucormycosis.
References
Petrikkos G, Skiada A, Lortholary O, Roilides E,
Walsh TJ, Kontoyiannis DP. Epidemiology and clinical
manifestations of mucormycosis. Clin Infect Dis.
;54;1:S23-34.
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis
DP. Pathogenesis of mucormycosis. Clin Infect Dis.
;54;1:S16-22.
Gutiérrez-Delgado EM, Treviño-González JL,
Montemayor-Alatorre A, Ceceñas-Falcón LA, Ruiz-
Holguín E, Andrade-Vázquez CJ et al. Chronic
rhino-orbito-cerebral mucormycosis: A case report
and review of the literature. Ann Med Surg (Lond).
;6:87-91.
Mahalaxmi I, Jayaramayya K, Venkatesan D,
Subramaniam MD, Renu K, Vijayakumar P et al.
Mucormycosis: an opportunistic pathogen during
COVID-19. Environ Res. 2021;201:111643.
Mangal R, Gehlot PS, Bang A, Kaushal A, Kolare
R. COVID-19 Associated Rhino-orbito-cerebral
Mucormycosis: Clinical Profile and Imaging Spectrum.
J Clin Diagn Res. 2021;15;9:1-6.
Banerjee A, Das M, Verma P, Chatterjee A, Ramalingam
K, Srivastava KC. COVID-19 and mucormycosis
of orofacial region: A scoping review. Cureus.
;15(4):e37984.
Talmi YP, Goldschmied-Reouven A, Bakon M,
Barshack I, Wolf M, Horowitz Z et al. Rhino-orbital
and rhino-orbito-cerebral mucormycosis. Otolaryngol
Head Neck Surg. 2002;127:22-31.
Werthman-Ehrenreich A. Mucormycosis with orbital
compartment syndrome in a patient with COVID-19.
Am J Emerg Med. 2021;42:264.e5-8.
Vadivel S, Gowrishankar M, Vetrivel K, Sujatha B,
Navaneethan P. Rhino orbital cerebral mucormycosis
in Covid-19 crisis. Indian J Otolaryngol Head Neck
Surg. 2023;75;1:1014-20.
Moorthy A, Nayak T, Bachalli PS, Tripathi KK, Dutt
SN, Kale P et al. COVID-associated rhinocerebral
mucormycosis: a retrospective analysis of presentation
and outcomes. Eur Arch Otorhinolaryngol.
;280:713-21.
Chillana S, Mohit Chilana KA. COVID-19 and
mucormycosis: A black fungus disaster? Indian J
Dermatol. 2022;67:535-8.
Watanabe A, So M, Mitaka H, Ishisaka Y, Takagi H,
Inokuchi R, Iwagami M, Kuno T. Clinical features and
mortality of COVID-19-associated mucormycosis: a
systematic review and meta-analysis. Mycopathologia.
;187:271-89.
Kamat M, Datar U, Byakodi S, Kamat S, Vimal Kumar
V. COVID-19-associated mucormycosis of head-andneck
region: A systematic review. J Clin Transl Res.
;8:31-42.
Singh P, Arora S, Mittal N, Singh A, Verma R, Sharma S
et al. Diabetes and rhino-orbito-cerebral mucormycosis
- A deadly duo. J Diabetes Metab Disord. 2021;20:201-
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA,
Sarkisova TA, Schaufele RL et al. Epidemiology and
outcome of Zygomycosis: a review of 929 reported
cases. Clin Infect Dis. 2005;41:634-53.
Paidisetty P, Nagose V, Vaze V, Mahajan N, Rathod
S. Changing trend of risk factors of mucormycosis
including diabetes, acidosis, and serum iron in
the second wave of COVID-19. Indian J Microbiol.
;62:602-9.
Negm EM, Mohamed MS, Rabie RA, Fouad WS,
Beniamen A, Mosallem A et al. Fungal infection profile
in critically ill COVID-19 patients: a prospective
study at a large teaching hospital in a middle-income
country. BMC Infect Dis. 2023;23:246.
Bhandari S, Bhargava S, Samdhani S, Singh SN,
Sharma BB, Agarwal S et al. COVID-19, diabetes and
steroids: the demonic trident for mucormycosis. Indian
J Otolaryngol Head Neck Surg. 2022;74:3469-72.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA,
Kong DCM, Chen SC. The epidemiology and clinical
manifestations of mucormycosis: a systematic review
and meta-analysis of case reports. Clin Microbiol
Infect. 2019;25:26-34.
Kumar A, Kumar A, Kumar N, Kumar A, Sinha
C, Singh PK. Does long-term oxygen therapy and
noninvasive ventilation predispose rhino-orbitalcerebral
mucormycosis in COVID-19 patients? Indian J
Crit Care Med. 2022;26:1063-4.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.